In vivo irradiations with patients undergoing radiation therapy: dana farber canc

接受放射治疗的患者的体内照射：达纳法伯癌症

• 批准号: 8013161
• 负责人: EVA C GUINAN
• 金额: $ 28.05万
• 依托单位: DARTMOUTH COLLEGE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-08-15 至 2015-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8013161
• 关键词: Acute; Animal Model; Biological Assay; Calibration; Clip; Development; Dose; Evaluation Methodology; Event; Exposure to; Feedback; Goals; Human; Human Resources; Individual; Ionizing radiation; Measurement; Measures; Methodology; Methods; Myelosuppression; Nail plate; Patients; Population; Procedures; Protocols documentation; Radiation; Radiation Syndromes; Radiation therapy; Research; Role; Sampling; Staging; Techniques; Technology; Testing; Tooth structure; Triage; Whole-Body Irradiation; Work; base; biodosimetry; clinically significant; design; human subject; in vivo; instrument; irradiation; meetings; member; operation; programs; prototype; response; technique development

This core will have a critically important role in all 3 projects, providing access to a population of pafients that provide a unique opportunity to develop the techniques and test the instrumentafion that is being developed. One of the potentially limiting factors in the development of accurate and effecfive biodosimetry for triage of large populations potenfially exposed to clinically significant levels of ionizing radiafion has been the lack of suitable samples and subjects to test the validity ofthe assays and to facilitate the development of the techniques. Suitable samples/subjects require exposure to ionizing radiation in the dose range leading to the acute radiation syndrome, (2 -12 Gy). It would be completely unethical to expose human individuals to such doses of radiation for the purpose of developing the methodology and evaluation in animal models is not pracfical or relevant at this stage of development. We can instead, however, utilize pafients who receive such radiafion exposures as part of their treatment for myelosuppression and immunosupression. The DFCI is one ofthe few places in the world where there are large numbers of patients who as a part of their therapy, receive TBI in the dose ranges that are direcfiy pertinent to the levels needed to be measured in the event of a radiafion exposure event. In addition, there are ongoing research programs at DFCI that are invesfigafing the effects of such irradiations and strategies to minimize the effects of the exposures. This provides a unique opportunity to carry out the much-needed development and validafion of a methodology designed to make such measurements as a means of facilitating an effecfive response to an event in which large numbers of people potenfially are exposed to clinically significant dose of ionizing radiafion. The personnel from the DFCI will work with the personnel from the projects to make measurements in the TBI patient populafion in vivo in teeth and nails. Clippings of nails also will be obtained for use by project 2. When the prototype instruments suitable for deployed use by non-expert personnel are constructed, measurements will be made at DFCI using members ofthe team that have not previously been involved with the operafion ofthe instruments, providing a realisfic test ofthe capabilifies ofthe design, with important feedback for improvement of the prototypes.

该核心将在所有 3 个项目中发挥至关重要的作用，为 为开发技术和测试正在开发的仪器提供了独特的机会。发展准确有效的潜在限制因素之一 用于对可能暴露于临床上显着水平的电离辐射的大量人群进行分类的生物剂量测定法一直缺乏合适的样品和受试者来测试测定的有效性并促进技术的发展。合适的样品/受试者需要暴露于导致急性辐射综合征的剂量范围内的电离辐射（2 -12 Gy）。为了开发方法而将人类暴露于如此剂量的辐射是完全不道德的，并且在动物模型中进行评估在现阶段不切实际或不相关。然而，我们可以利用接受此类辐射暴露的患者作为骨髓抑制和免疫抑制治疗的一部分。 DFCI 是世界上少数几个有大量患者接受 TBI 治疗的地方之一，其剂量范围与发生辐射暴露事件时需要测量的水平直接相关。此外，DFCI 正在进行的研究项目正在调查此类辐射的影响以及尽量减少辐射影响的策略。这提供了一个独特的机会来进行急需的方法的开发和验证，该方法旨在进行此类测量，作为促进对大量人员可能暴露于临床显着剂量的电离辐射的事件进行有效响应的手段。 DFCI 的人员将与项目人员合作，对 TBI 患者群体的牙齿和指甲进行体内测量。还将获得剪下的指甲供项目 2 使用。当构建出适合非专家人员部署使用的原型仪器时，将使用以前未参与过仪器操作的团队成员在 DFCI 进行测量，提供对设计能力的实际测试，并为改进原型提供重要反馈。